The U.S. Food and Drug Administration has extended its review of Novo Nordisk A/S’ (NYSE:NVO) Biologics License Application for denecimig, an investigational hemophilia A treatment, following a manufacturing plant inspection.
Mike Doustdar, president and CEO of Novo Nordisk, said the company is addressing agency requests as efficiently as possible while working closely with regulators to make better care something patients can count on.
Facility Remediation Extends FDA Review Period
Novo Nordisk submitted the application in September 2025 and anticipated a regulatory decision in the third quarter of 2026.
After a pre-license inspection of the manufacturing site, the FDA provided feedback that required facility remediation activities.
The ongoing remediation led directly to the extension of the review, although the agency has not communicated a new timeline for expected action.
Federal regulators identified no deficiencies related to safety or clinical efficacy data, and the facility feedback does not affect other marketed products.
Financial Outlook Intact Ahead Of Planned 2027 Launch
Pending approval, the company intends to launch denecimig in the United States during the first half of 2027.
In September, the therapy received a positive CHMP opinion and now awaits marketing approval from the EMA, alongside ongoing reviews by other international regulatory authorities.
Trial Program Evaluates Multiple Prophylactic Regimens
Denecimig is a subcutaneous FVIIIa mimetic bispecific antibody administered to prevent bleeding episodes in adults and children with or without inhibitors.
The subcutaneous treatment bridges factor IXa and factor X, mimicking FVIIIa cofactor function to restore thrombin generation capacity. The broad FRONTIER clinical program encompasses FRONTIER1 through FRONTIER5.
Data from FRONTIER2, FRONTIER3, and FRONTIER4 formed the foundation for the Marketing Authorization Application.
FRONTIER2 assessed monthly and weekly dosing in patients 12 and older, while FRONTIER3 evaluated monthly and weekly regimens in children under 12.
FRONTIER4, an open-label extension study, examined biweekly efficacy alongside long-term safety across all three dosing schedules.
NVO Price Action: Novo Nordisk shares were down 1.17% to $36.88 at the time of publication on Monday, according to Benzinga Pro data.
Image via Shutterstock
Login to comment